

Cite this: *Dalton Trans.*, 2017, **46**, 12114

## Synthesis and *in vivo* anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates†

Carmen M. Hackl,<sup>‡a</sup> Beatrix Schoenhacker-Alte,<sup>‡a,b,d</sup> Matthias H. M. Klose,<sup>id a</sup> Helena Henke,<sup>id c</sup> Maria S. Legina,<sup>a</sup> Michael A. Jakupec,<sup>id a,d</sup> Walter Berger,<sup>id b,d</sup> Bernhard K. Keppler,<sup>a,d</sup> Oliver Brüggemann,<sup>c</sup> Ian Teasdale,<sup>id c</sup> Petra Heffeter<sup>\*b,d</sup> and Wolfgang Kandioller<sup>id \*a,d</sup>

Within this work we aimed to improve the pharmacodynamics and toxicity profile of organoruthenium and -rhodium complexes which had previously been found to be highly potent *in vitro* but showed unselective activity *in vivo*. Different organometallic complexes were attached to a degradable poly(organo)phosphazene macromolecule, prepared *via* controlled polymerization techniques. The conjugation to hydrophilic polymers was designed to increase the aqueous solubility of the typically poorly soluble metal-based half-sandwich compounds with the aim of a controlled, pH-triggered release of the active metallodrug. The synthesized conjugates and their characteristics have been thoroughly studied by means of <sup>31</sup>P NMR and UV-Vis spectroscopy, ICP-MS analyses and SEC coupled to ICP-MS. In order to assess their potential as possible anticancer drug candidates, the complexes, as well as their respective macromolecular prodrug formulations were tested against three different cancer cell lines in cell culture. Subsequently, the anticancer activity and organ distribution of the poly(organo)phosphazene drug conjugates were explored *in vivo* in mice bearing CT-26 colon carcinoma. Our investigations revealed a beneficial influence of this macromolecular prodrug by a significant reduction of adverse effects compared to the free metallodrugs.

Received 15th May 2017,  
Accepted 4th July 2017

DOI: 10.1039/c7dt01767g

rsc.li/dalton

## Introduction

One of the most frequent reasons for premature discontinuation of clinical trials is the occurrence of unforeseen side effects caused by the novel drug candidates.<sup>1–3</sup> A promising research branch sprouting from the intention to selectively target solid tumors makes use of the enhanced permeability and retention (EPR) effect. This effect describes the accumulation of macromolecules by passive diffusion into tumor tissues which are usually characterized by an abnormal vascu-

lature and irregular architecture of cell layers.<sup>4–6</sup> Leakages in the endothelial layer of capillaries permit the infiltration of the intercellular space of tumor tissues by macromolecules, where they are retained due to deficient lymphatic drainage. One of the leading and most elegant strategies to exploit this effect is based on the utilization of human serum albumin (HSA) as a natural transport vehicle.<sup>7–9</sup> Approval was granted to an albumin nanoformulation of the established drug paclitaxel (trade name: Abraxane®) for the treatment of different cancer types, with especially high responses in breast cancer therapy.<sup>7</sup> The fundamental role of HSA is also reflected in the minor side-effects of the first-in-class drug candidate IT-139 (NKP-1339; sodium *trans*-[tetrachloridobis(1*H*-indazole) ruthenate(III)]), which is attributed to its high affinity for human serum albumin. In this special case, binding occurs non-covalently at hydrophobic domains of the protein, allowing for the attachment of more than one drug unit per HSA molecule.<sup>8</sup> As for synthetic macromolecules, next to fulfilling certain size requirements to utilize the EPR effect (commonly 20–200 kDa),<sup>9</sup> a potential drug carrier has to guarantee controlled release of the active load at the biological target.<sup>10</sup> Hence, an exclusive trigger that can initiate drug release from

<sup>a</sup>Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090 Wien, Austria. E-mail: wolfgang.kandioller@univie.ac.at

<sup>b</sup>Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria. E-mail: petra.heffeter@meduniwien.ac.at

<sup>c</sup>Institute of Polymer Chemistry, Johannes Kepler University Linz (JKU), Altenberger Straße 69, 4040 Linz, Austria

<sup>d</sup>Research Cluster "Translational Cancer Therapy Research", University of Vienna, Waehringer Str. 42, 1090 Wien, Austria

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c7dt01767g

‡These authors contributed equally.



a macromolecular prodrug under the given circumstances must be identified. In poly(organo)phosphazenes deliberate selection of building blocks grants extensive control over essential characteristics such as degradation rate and aqueous solubility.<sup>11,12</sup> Additionally, the degradable backbone, suitable functional groups, and the degradation into physiologically nonhazardous metabolites satisfy several of the conditions required for polymer therapeutics.<sup>10</sup> As previously shown for platinum-based anticancer drugs coupled to polyphosphazene structures, the cellular uptake and accumulation into tumor tissue of such macromolecular drug formulations could be significantly increased compared to the free drug. The *in vivo* evaluation of polyphosphazenes equipped with established platinum(II) drugs capable of assembling into either micelles or nanoparticles of suitable diameters revealed pronounced accumulation within the tumor, while only low platinum levels were detected in healthy tissues.<sup>13–15</sup> Furthermore, we recently investigated the effect of polyphosphazene conjugation with representatives of the supposedly more inert class of Pt<sup>IV</sup> prodrugs. In this work we observed a 30-fold increase in cellular uptake and at the same time an increase in cytotoxic activity *in vitro*. While Pt<sup>II</sup> compounds such as cisplatin or carboplatin reign supreme in cytotoxic activity, these polymer–drug conjugates were shown to accumulate as well in tested cisplatin-resistant cell lines, where they were nevertheless able to exert their cytotoxic effect.<sup>16</sup> The beneficial influence of macromolecular drug delivery on the pharmaceutical efficacy has been adopted likewise for the conjugation of promising organometallic anticancer agents and several interesting approaches are described in the literature.<sup>17</sup>

The extensive collection of organometallic half-sandwich complexes comprises many representatives that have been assessed in a variety of *in vitro* and *in vivo* studies where they exhibited great potential as cytotoxic agents.<sup>18–20</sup> The assumed mode of action of this compound class is associated with an aquation step wherein an aqua ligand replaces the leaving group. In a prior attempt to stabilize highly cytotoxic thio-maltolato complexes in the presence of biomolecules the N-donating ligand 1-methylimidazole was employed as leaving group.<sup>21</sup> Thus, the stability was significantly increased and selective activation was possible at decreased pH levels, that are frequently found in solid tumors.<sup>22</sup> Hence, these promising results prompted us to develop polyphosphazene conjugates *via* coordination of the free amine linker group to different organometallic compounds of known activity. The

pH-sensitivity of both polyphosphazene backbone and drug–amine interaction are eligible characteristics for the application of the respective drug–polymer conjugates in targeted therapy. In our approach, four promising organometallic complexes (Fig. 1) with small molecule ligands of known biological activity were chosen in order to improve their *in vivo* activity profile, which was shown to involve local adverse effects in a previously performed test series.

## Experimental

### Materials

Menadione (2-methylnaphthalene-1,4-dione, 98%, Acros), sodium methoxide (*ca.* 95%, Fluka),  $\alpha$ -terpinene (90%, Acros), RuCl<sub>3</sub>·H<sub>2</sub>O (Johnson Matthey), trifluoroacetic acid (99%, Sigma-Aldrich), triethylamine (99%, Acros), ammonium acetate ( $\geq$ 98%, Fluka), citric acid anhydrous (99.6%, Acros), trisodium citrate dihydrate (min. 99.5%, Sigma-Aldrich) were used without further purification. Other chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, Merck, Acros, Fluka and Fisher Scientific). Methanol and dichloromethane were distilled prior to use. Dialysis membranes (Spectra/Por 1, 6000–8000 Da) were purchased from SpectrumLabs. NMR spectra were recorded at 25 °C on a Bruker Avance III™ 500 MHz FT-NMR spectrometer. <sup>1</sup>H NMR spectra were measured at 500.10 MHz, <sup>13</sup>C NMR spectra at 125.75 MHz and {<sup>1</sup>H}<sup>31</sup>P NMR spectra at 202.44 MHz from solutions in deuterated dimethyl sulfoxide, methanol, chloroform, and water. Milli-Q water (18.2 M $\Omega$  cm, Milli-Q Advantage, Darmstadt, Germany) was used for all dilutions for ICP-MS measurements. Nitric acid ( $\geq$ 69%, p.a., TraceSELECT®, Fluka, Buchs, Switzerland) was used without further purification. Ruthenium, rhodium and indium standards for ICP-MS measurements were derived from CPI International (Amsterdam, The Netherlands). Bovine serum albumin (BSA) (>98%, Sigma) and Uracil (99%, Fluka) for calibration of the column for SEC-ICP-MS studies were used without further purification. CHNS elemental analyses were carried out on a Eurovector EA3000 elemental analyzer in the microanalytical laboratory of the University of Vienna.

A detailed description of the synthetic procedures for the ligands, complex 1 as well as for the used polymer is given in the ESI.†

### General synthetic procedures

**General procedure for the synthesis of ruthenium and rhodium complexes.** Syntheses of complexes 1–4 were performed according to the well-established protocol using sodium methoxide in absolute methanol to deprotonate the respective chelating ligand followed by the addition of the dimeric metal precursor complex [( $\eta^6$ -*p*-cymene)Ru<sup>II</sup>Cl<sub>2</sub>]<sub>2</sub> or [( $\eta^5$ -1,2,3,4,5-pentamethylcyclopentadien)Rh<sup>III</sup>Cl<sub>2</sub>]<sub>2</sub>. After stirring at ambient temperature for a varying reaction time ranging from 1.5 to 24 h, the solvent was removed under




Fig. 1 Complexes 1–4 prepared for macromolecular conjugation.



reduced pressure, the crude product was extracted with dichloromethane and insoluble by-products were removed by filtration. The mixture was then concentrated and the addition of *n*-hexane afforded the desired complexes in good to excellent yields. Detailed reaction conditions for complexes 2–4 are described elsewhere.<sup>21,23,24</sup>

**General procedure for deprotection and loading of polyphosphazenes.** For the removal of the *tert*-butyloxycarbonyl (Boc) protecting group, the poly(organo)phosphazene was dissolved in a dry CH<sub>2</sub>Cl<sub>2</sub>/TFA mixture (2:1 ratio, 2 mL per 100 mg polymer) and stirred under argon atmosphere for 1 h. After evaporation of the solvent mixture under reduced pressure, the deprotected polyphosphazene was dried *in vacuo*. In order to form drug-loaded polymer conjugates, the deprotected polyphosphazene was dissolved in dry methanol and Et<sub>3</sub>N was added to the mixture. The methanolic solution of the respective complex was carefully added to the polymer and the coupling reaction was stirred at room temperature and under argon atmosphere for 24 h. Conjugates were then purified by dialysis against methanol for 5 days.

**Conjugate 1a:** Deprotected polymer (300 mg, 0.016 mmol), complex 1 (150 mg, 0.33 mmol), Et<sub>3</sub>N (55 μL, 0.40 mmol); yield: 187 mg; <sup>1</sup>H NMR (500.10 MHz, D<sub>2</sub>O): δ 1.11 (m, 6H), 1.37 (m, 4H), 3.17 (s, 6H), 3.31 (bs, 6H), 3.63 (s, 154H) ppm. {<sup>1</sup>H}<sup>31</sup>P NMR (202.44 MHz, D<sub>2</sub>O): δ 0.21 ppm. DLS (H<sub>2</sub>O): *d*<sub>h</sub> = 16.5 nm; ξ = 1.75 mV. **Conjugate 2a:** Deprotected polymer (300 mg, 0.016 mmol), complex 2 (150 mg, 0.36 mmol), Et<sub>3</sub>N (55 μL, 0.40 mmol); yield: 205 mg; <sup>1</sup>H NMR (500.10 MHz, D<sub>2</sub>O): δ 1.02 (m, 6H), 1.12 (m, 4H), 3.19 (s, 6H), 3.23 (bs, 6H), 3.55 (s, 156 H) ppm. {<sup>1</sup>H}<sup>31</sup>P NMR (202.44 MHz, D<sub>2</sub>O): δ 0.16 ppm. DLS (H<sub>2</sub>O): *d*<sub>h</sub> = 11.7 nm; ξ = 5.92 mV. **Conjugate 3a:** Deprotected polymer (300 mg, 0.014 mmol), complex 3 (150 mg, 0.36 mmol), Et<sub>3</sub>N (55 μL, 0.40 mmol); yield: 161 mg; <sup>1</sup>H NMR (500.10 MHz, D<sub>2</sub>O): 1.07 (m, 6H), 1.20 (m, 4H), 3.13 (s, 6H), 3.29 (bs, 6H), 3.61 (s, 151H) ppm. {<sup>1</sup>H}<sup>31</sup>P NMR (202.44 MHz, D<sub>2</sub>O): δ 0.86 ppm. DLS (H<sub>2</sub>O): *d*<sub>h</sub> = 11.9 nm; ξ = 2.85 mV. **Conjugate 4a:** Deprotected polymer (300 mg, 0.016 mmol), complex 4 (150 mg, 0.28 mmol), Et<sub>3</sub>N (55 μL, 0.40 mmol); yield: 216 mg; <sup>1</sup>H NMR (500.10 MHz, D<sub>2</sub>O): 1.03 (m, 6H), 1.18 (m, 4H), 3.17 (s, 6H), 3.33 (bs, 3H), 3.57 (s, 160H) ppm. {<sup>1</sup>H}<sup>31</sup>P NMR (202.44 MHz, D<sub>2</sub>O): δ 0.93 ppm. DLS (H<sub>2</sub>O): *d*<sub>h</sub> = 13.1 nm; ξ = 0.58 mV.

### ICP-MS analyses

Quantification of metal content of conjugates 1a–4a as well as the determination of the ruthenium/rhodium content in tissue and blood samples from *in vivo* experiments was carried out with an ICP-MS instrument Agilent 7500ce. The ICP-MS Agilent 7500ce (Agilent Technologies, Waldbronn, Germany) was equipped with a CETAC ASX-520 autosampler (Nebraska, USA) and a MicroMist nebulizer at a sample uptake rate of approx. 0.25 mL min<sup>-1</sup>. The Agilent MassHunter software package (Workstation Software, version B.01.01, Build 123.11, Patch 4, 2012) was used for data processing. The experimental parameters for ICP-MS analyses are summarized in Table S1†

and detailed description of sample preparation procedures can be found in the section S2.4 in the ESI.†

### General procedures for biological studies

**Animals and xenograft experiments.** Eight-week-old Balb/c or C57/B6JRj mice were purchased from Harlan Laboratories (San Pietro al Natisone, Italy). The animals were kept in a pathogen-free environment and every procedure was done in a laminar airflow cabinet. The experiments were done according to the regulations of the Ethics Committee for the Care and Use of Laboratory Animals at the Medical University Vienna (proposal number BMWF-66.009/0084-II/3b/2013), the U.S. Public Health Service Policy on Human Care and Use of Laboratory Animals as well as the United Kingdom Coordinating Committee on Cancer Prevention Research's Guidelines for the Welfare of Animals in Experimental Neoplasia.

For the evaluation of tolerability and 24 h organ distribution, non-tumor bearing C57/B6JRj mice were treated with a single dose of the drug conjugates 1a, 2a or 3a *via* intravenous administration. The doses used were 100 mg kg<sup>-1</sup> for 1a, 25, 50 and 100 mg kg<sup>-1</sup> for 2a and 50 and 100 mg kg<sup>-1</sup> for 3a. Animals were sacrificed 24 h after administration of the compounds.

For the testing of *in vivo* anticancer activity, CT-26 (5 × 10<sup>5</sup>) were injected subcutaneously into the right flank of Balb/c mice. When tumor nodules reached a mean size of 25 mm<sup>3</sup> (day 3), animals were treated twice for five consecutive days (day 3–7 and 10–15) in groups of four with 1 (30 mg kg<sup>-1</sup> in 10% DMSO in water), 2 (10 mg kg<sup>-1</sup> in 10% DMSO in water) and 3 (10 mg kg<sup>-1</sup> in 10% PG in water) by intraperitoneal injection. Compounds 1a–3a were dissolved in 0.9% NaCl solution and sterile filtered afterwards. Animals were treated intravenously with compound 1a, 3a (both 50 mg kg<sup>-1</sup>) and 2a (25 mg kg<sup>-1</sup>) on days 3, 5, 7, 10, 12 and 14 after the injection of tumor cells. The tumor size was assessed by caliper measurement and tumor volume was calculated using the formula: (length × width<sup>2</sup>)/2. Animals were sacrificed upon tumor ulceration or when a tumor length >20 mm was reached.

**Cell culture.** In the presented study, the following cell lines were used: the human cell line CH1 (identified *via* STR profiling as PA-1 ovarian teratocarcinoma cells by Multiplexion; see also ref. 25) was kindly provided by Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK), and the colon cancer cell line SW480 was purchased from American Tissue Culture Collection (ATCC). These two cell lines were grown in MEM (supplemented with 1% L-glutamine, 1% sodium pyruvate, and 1% non-essential amino acids solution (all from Sigma Aldrich, Austria, Vienna) and 10% FCS (Gibco™, ThermoFisher)). The non-small cell lung carcinoma cell line A549 was purchased from ATCC and grown in RPMI 1640 supplemented with 10% FCS. The murine colon cancer cell line CT-26 (purchased from ATCC) was grown in DMEM/F12 medium (Sigma-Aldrich) supplemented with 10% FCS. FCS was purchased from PAA (Linz, Austria). All cultures were grown in humidified air with 5% CO<sub>2</sub> at 37 °C and were regularly checked for mycoplasma contamination.



**Cell viability assay (MTT).** 96 h cytotoxicity was determined by the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Briefly, cells were harvested by trypsinisation and seeded in medium (*vide supra*) into 96-well plates in 100  $\mu\text{L}$  per well. The following densities were used to ensure exponential growth of untreated controls throughout the experiment:  $1.0 \times 10^3$  (CH1/PA-1),  $2.0 \times 10^3$  (SW480),  $3.0 \times 10^3$  (A549) cells per well. For 24 h, cells were allowed to settle and resume exponential growth. Then the test compounds were dissolved and serially diluted in medium with 100  $\mu\text{L}$  per well. After 96 h at 37  $^\circ\text{C}$ , the medium was replaced with 100  $\mu\text{L}$  per well RPMI 1640 medium (supplemented with 10% FCS and 4 mM L-glutamine) and MTT solution (MTT reagent in phosphate-buffered saline, 5 mg  $\text{mL}^{-1}$ ) in a ratio of 6:1, and plates were incubated for further 4 h. Then medium/MTT was removed, and the formed formazan was dissolved in DMSO (150  $\mu\text{L}$  per well). Optical densities at 550 nm were measured (reference wavelength: 690 nm) with a microplate reader (ELX880, BioTek). The quantity of viable cells was expressed relative to untreated controls, and 50% inhibitory concentrations ( $\text{IC}_{50}$ ) were interpolated. At least three independent experiments were performed, each with triplicates per concentration level.

**Viability assay (EZ4U).** For the 72 h viability experiments, cells were plated in 100  $\mu\text{L}$  per well in 96-well plates. The number of cells per well was A549 ( $2 \times 10^3$ ), CH1/PA-1 ( $3 \times 10^3$ ), SW480 ( $2 \times 10^3$ ), and CT-26 ( $3 \times 10^3$ ). Cells were allowed to recover for 24 h, then drugs were added in another 100  $\mu\text{L}$  growth medium and cells were exposed for the time indicated. Cell survival was determined by the EZ4U assay following the manufacturer's recommendations (Biomedica, Vienna, Austria). Cytotoxicity was evaluated using the Graph Pad Prism software (La Jolla, USA) (using a point-to-point function) and was expressed as  $\text{IC}_{50}$  values calculated from full dose-response curves (drug concentrations resulting in 50% reduction of viable cells compared to untreated control cells cultured in parallel).

**Cellular drug uptake studies.** Sample preparation from cell culture:  $3 \times 10^5$  cells per well were seeded in 6-well-plates and allowed to recover for 24 h, then the cells were treated with 10  $\mu\text{M}$  solution of compounds 1–4 or an equimolar amount of conjugates 1a–4a, respectively. All compounds were added in culture medium with 10% FCS and incubated for 3 h at 37  $^\circ\text{C}$ . Cells were washed twice with PBS. Then, the pellet was lysed in 500  $\mu\text{L}$  of 69%  $\text{HNO}_3$  at room temperature for 1.5 h. 400  $\mu\text{L}$  of the resulting lysates were diluted in 8 mL Milli-Q water and measured by ICP-MS instrument Agilent 7500ce as described above (see ref. 26).

## Results and discussion

### Synthesis and biological characterization of the Ru<sup>II</sup> and Rh<sup>III</sup> organometallic complexes

For the synthesis of complexes 1–4, the respective ligands 2-hydroxy-3-methyl-1,4-naphthoquinone, 2-hydroxy-3-methyl-

pyran-4(1H)-thione and 3-hydroxy-2-(4-chlorophenyl)-4H-chromen-4(1H)-one were synthesized according to established, straightforward procedures (Schemes S1–S3†). The synthesis of the naphthoquinone derivative started from the commercially available menadione (2-methyl-1,4-naphthoquinone) which was converted into the corresponding epoxide by reaction with sodium hydroxide and hydrogen peroxide in a methanol/water mixture, followed by acid catalyzed ring opening on silica.<sup>27</sup> Commercially available maltol represented the starting point for the synthesis of the second ligand, thiomaltol. Lawesson's reagent, a standard compound for thionation reactions, was applied to convert the carbonyl group into the respective thiocarbonyl *via* the replacement of the oxygen by sulfur.<sup>28</sup> Finally, in order to synthesize the desired flavone ligand, 2-hydroxyacetophenone and 4-chlorobenzaldehyde were reacted in a classic aldol condensation to give the hydroxychalcone intermediate with subsequent ring closing under Algar–Flynn–Oyamada reaction conditions to afford the flavonol ligand.<sup>29</sup> Complexes 1–4 (Fig. 1) were synthesized by deprotonation of the ligands' hydroxyl group by sodium methoxide in methanol followed by the addition of the respective dimeric metal precursor as has been reported previously for compounds 2, 3, and 4.<sup>21,23,24</sup> The synthesis of the thiomaltolato-based ruthenium(II) and rhodium(III) complexes required exclusion of water and oxygen from the reaction vessel in order to circumvent side reactions. Hence, reactions were performed in dry methanol using Schlenk techniques. Standard analytical methods including <sup>1</sup>H and <sup>13</sup>C NMR, elemental analysis, and X-ray diffraction analysis were performed and the obtained data was compared to the respective literature data to confirm purity and formation of the desired organometallics (reaction scheme and NMR spectra of complex 1 are shown in the ESI, Scheme S4 and Fig. S1 and S2†). The compounds were then tested for their anticancer activity in an MTT assay in three human cancer cell lines with an exposure time of 96 h, where they displayed varying cytotoxic potencies depending on the cell line (Table 1). Cytotoxicity decreases in the following order:  $3 \geq 4 > 2 > 1$ . Even compound 1 displaying the highest  $\text{IC}_{50}$  values can still be considered a valid candidate for *in vivo* assessment, as its  $\text{IC}_{50}$  values are lower than those of the clinically active investigational ruthenium drug IT-139.

Subsequently, complexes 1–3 were evaluated for their *in vivo* anticancer activity against murine CT-26 colon carcinoma cells. Unfortunately, the poor solubility of complex 4 precluded

**Table 1** Comparison of  $\text{IC}_{50}$  values of compounds 1–4 after 96 h of incubation

$\text{IC}_{50}$ [ $\mu\text{M}$ ]	A549	CH1/PA-1	SW480
1	47 $\pm$ 4	31 $\pm$ 10	15 $\pm$ 3
2	12 $\pm$ 4	2.9 $\pm$ 0.7	3.7 $\pm$ 1.0
3 <sup>a</sup>	5.9 $\pm$ 0.8	0.97 $\pm$ 0.11	1.0 $\pm$ 0.1
4 <sup>b</sup>	9.5 $\pm$ 0.5	0.86 $\pm$ 0.06	3.8 $\pm$ 0.5
IT-139 <sup>c</sup>	156 $\pm$ 11	62 $\pm$ 9	88 $\pm$ 19

$\text{IC}_{50}$  data taken from <sup>a</sup> Ref. 21. <sup>b</sup> Ref. 24. <sup>c</sup> Ref. 30.



further *in vivo* investigations with this compound. For the experiments Balb/c mice bearing the syngeneic tumor cells were treated intraperitoneally with the drugs applied at their maximal tolerated dose of 30 mg kg<sup>-1</sup> for compound 1 and 10 mg kg<sup>-1</sup> for compound 2 and 3. In these experiments, only compound 1 exerted significant activity ( $p < 0.01$  by two-way-ANOVA and Bonferroni posttest) (Fig. 2) and lowered the tumor burden of the treated animals on the final day of the experiment (data not shown). In contrast, compound 2 and 3 were widely inactive. Remarkably, the dissection of the animals revealed strong local adverse effects at multiple organs in the abdominal cavity, *e.g.*, stiff and swollen intestine, lesions on the liver, and spleen grown together with liver and stomach (Fig. S9†) for complexes 1–3. Consequently, we hypothesized that the compounds exerted excessive local reactivity, which prevented sufficient amounts of drug to be delivered to the malignant tissue. Thus, a nanoformulation approach using polymer conjugates to avoid local reactions and facilitate drug transport into the tumor nodules was chosen as the next step.

### Synthesis and characterization of the polyphosphazene conjugates

Star-branched polyphosphazenes were utilized as macromolecular drug carriers due to their excellent aqueous solubility and highly branched architecture.<sup>31,32</sup> Polymers were synthesized *via* living cationic polymerization providing control over chain length and molecular weight.<sup>33,34</sup> In a successive two-step post-polymerization substitution the chlorine atoms of the poly(dichlorophosphazene) [NPCl<sub>2</sub>]<sub>n</sub> were partially substituted with mono-Boc-protected 2,2'-(ethylenedioxy)-bis(ethylamine) introducing the reaction sites, which were used for coordination to the organometallic complexes after deprotection. In the next step complete substitution of the remaining chlorine atoms with Jeffamine, a mono-amine PPO-PEO random copolymer ( $M_n = 1000$ ) was performed, resulting in highly branched and water-soluble polymers (Scheme S5†). The percentage of reactive sites was determined *via* <sup>1</sup>H NMR spectroscopy by calculating the ratio of the integrated Boc-group signal to the OCH<sub>3</sub> end group peak of the Jeffamine moieties (29% Boc-groups). <sup>1</sup>H and <sup>31</sup>P NMR spectra are shown in the ESI (Fig. S3 and S4†). The Boc-protecting

group was cleaved under dry, acidic conditions yielding free amino groups which were subsequently used to form coordinative bonds with the organometallic complexes 1–4 in methanolic solution, affording the desired conjugates after purification *via* dialysis. The obtained products were dried under reduced pressure, dissolved in water and lyophilized. For subsequent investigations, conjugates were dissolved in a 0.9% sodium chloride solution and stored at –80 °C.

In order to evaluate the degradation behavior of conjugates during storage in 0.9% sodium chloride solution, <sup>31</sup>P NMR spectra were periodically measured over four weeks. The collected spectra confirmed the suitable stability of all prepared conjugates after several weeks in aqueous solution (Fig. S5†).

The rate of degradation of polyphosphazenes can be readily tailored and these polymers were chosen from previous studies to have a relatively slow degradation rate to simplify these preliminary drug conjugation studies.<sup>35</sup> The extent of drug loading was determined by measurement of the metal content *via* ICP-MS analyses. Sample preparation involved the microwave-assisted digestion of the poly(organo)phosphazene backbone in nitric acid (20%) to guarantee complete release of the metal. The samples were then diluted with Milli-Q water resulting in nitric acid concentrations below 4% and ruthenium or rhodium concentrations below 15 µg kg<sup>-1</sup>, suitable for ICP-MS analysis. Conjugates 2a and 3a, both bearing thio-maltolato-based complexes, show a high drug loading with 73.68 mg g<sup>-1</sup> ruthenium and 34.21 mg g<sup>-1</sup> rhodium (corresponds to an amine linker conversion of 85 and 40%, respectively), while lower ruthenium levels were detected for conjugates 1a and 4a (15 and 7% conversion; Table 2). Conjugate 4a was deemed not suitable for *in vivo* investigations due to its insufficient drug loading. As application of the conjugates *in vivo* requires sterile filtration through 0.2 µm cellulose acetate filters prior to the administration, the metal content was determined both before and after sterile filtration and showed no discernable effect of the filtration process on the metal contents of the samples.

**Drug-release studies.** One fundamental prerequisite for polymeric prodrugs is the controlled release of the active moiety in proximity to the biological target. There are several possible triggers to initiate the liberation of the drug. The hypoxic




Fig. 2 Anticancer activity of compounds 1–3 *in vivo*. CT-26 allografts were grown in Balb/c mice (four animals per group) and treated with (a) 1 (30 mg kg<sup>-1</sup> i.p.; male animals), (b) 2 (10 mg kg<sup>-1</sup> i.p.; male animals), and (c) 3 (10 mg kg<sup>-1</sup> i.p.; female animals) on days 3–7 and 10–15. \*\* $p < 0.01$  statistically different from solvent control by two-way ANOVA and Bonferroni post test.



**Table 2** Ruthenium and rhodium concentrations of analyzed aqueous polymer solutions acquired with ICP-MS measurements before and after sterile-filtration


Conjugate	Metal content [mg g <sup>-1</sup> ]	Metal concentration before filtration [mg mL <sup>-1</sup> ]	Metal concentration after filtration [mg mL <sup>-1</sup> ]
1a	12.08	0.23	0.24
2a	73.68	1.49	1.49
3a	34.21	0.63	0.65
4a	5.74	0.15	0.16

milieu in solid tumors induces a pH drop by up to 1 unit, which has been exploited for the development of pH sensitive macromolecules or linkers for drug-delivery systems.<sup>36,37</sup> Another common tactic is intracellular targeting by use of the lower pH of the endosomal and lysosomal environment.<sup>38</sup> The amine bond to the metal center is proposed to be sensitive to acidic cleavage (Fig. 3) as was demonstrated in our recently reported work on 1-methylimidazole substituted organometallic complexes.<sup>30</sup> Preliminary UV-Vis spectroscopic investigations indicated that the conjugates underwent the same transformation under acidic conditions (Fig. S6†). Complex 1 and conjugate 1a were diluted with citric acid buffer (50 mM, pH 3, 4, 5, and 6) and measured in 1 h intervals over a period of 24 h. While spectra recorded at pH 6 and 5 remained nearly

unchanged during the monitored time frame, the acidic milieu of pH 4 and 3 caused changes in the spectrum of 1a where the absorption at 280 nm increased similar to the free complex 1. Similar results were found for 2 and 2a under neutral and acidic conditions (data not shown). To confirm transformations of the conjugate at lower pH levels further studies using SEC-ICP-MS were performed using conjugate 2a. Again, the sensitivity of the conjugate to variations in the pH level became apparent in a different experimental setup using a mobile phase with 0.1 vol% formic acid. The acidic milieu (~pH 3) of the mobile phase led to the rapid decomposition of the conjugate and different ruthenium containing species were detected (Fig. S7†). The degradation process of the polymer was circumvented by use of an ammonium acetate buffered eluent (Fig. S8†). These experiments confirm that intracellular transformation of the conjugate under acidic conditions is possibly enabling the release of the attached metallo-drug (free and/or attached to linker). Further investigations on the exact transformation and release processes at lowered pH levels are necessary and will be subject of further research.

Recent studies have unveiled a certain affinity of albumin for ruthenium compounds. For this reason conjugate 2a was co-incubated with a 10-fold excess of bovine serum albumin (BSA) at 37 °C and analyzed by size-exclusion chromatography coupled ICP-MS measurements to rule out possible transfer processes of the ruthenium complex. The obtained results indicate that the metallodrug remains attached to the polymer in the presence of albumin under the given conditions. The chromatogram showed an undiminished ruthenium peak at the retention time corresponding to the polymer conjugate even after 24 h of incubation (Fig. S8†). To appraise the relative retention time of the conjugate when eluted in a mobile phase containing an ammonium acetate buffer (10 mM), size-exclusion chromatography (SEC) with a UV-Vis detector ( $\lambda = 240$  nm) were performed prior to SEC-coupled ICP-MS studies for the determination of the <sup>101</sup>Ru content.

**Evaluation of anticancer activity and drug uptake in cell culture.** Compounds 1–4 and their corresponding polymer-bound equivalents (conjugates 1a–4a) were analyzed in cell culture after 72 h of incubation (Table 3). These experiments revealed that the polymer formulation effectively protected the cells from the reactivity of the organometallic complexes,



**Fig. 3** Chemical structure of the macromolecular carriers and their proposed drug release mechanism at lowered pH shown for conjugate 1a.

**Table 3** Comparison of IC<sub>50</sub> values for free complexes 1–4 and conjugates 1a–4a after 72 h of incubation

IC <sub>50</sub> [μM]	A549	CH1/PA-1	SW480	CT-26
1	33 ± 3.3	32 ± 6.0	15 ± 6.2	>50
1a	>50	>50	>50	>50
2	16 ± 2.0	6.2 ± 0.8	15 ± 6.6	14 ± 0.4
2a	>50	>50	>50	>50
3	14 ± 5.5	2 ± 1.5	10 ± 4.1	9 ± 2.3
3a	25 ± 8.0	11 ± 1.5	11 ± 7.1	>50
4	13 ± 1.0	2 ± 0.4	7 ± 2.0	7 ± 2.4
4a	>50	>50	>50	>50




especially in case of conjugates **1a**, **2a** and **4a**. Only conjugate **3a** still displayed some activity in the  $\mu\text{M}$  range.

We have previously shown that the use of polyphosphazene nanocarriers can lead to increased drug uptake of metallo-drugs into cancer cells due to endocytosis.<sup>16</sup> Consequently, intracellular accumulation of all compounds was determined in two cell lines (Table 4). For this purpose, cells were treated with **1–4** ( $10 \mu\text{M}$ ) or equimolar amounts of **1a–4a** for 3 h. After lysis with  $\text{HNO}_3$  (69%), the samples were diluted and analyzed with ICP-MS for the determination of the metal content.<sup>26</sup> Surprisingly, the impact of the coupling to the phosphazene carrier differed between the tested compounds. Thus, in line with our previous publication on  $\text{Pt}^{\text{IV}}$ -polyphosphazene conjugates,<sup>16</sup> the intracellular accumulation of **2a** and **3a** was distinctly enhanced by the nanoformulation. This effect was especially pronounced with conjugate **2a**, which showed 15-fold and 11-fold higher intracellular accumulation compared to complex **2** in SW480 cells and in CT-26 cells, respectively. In contrast, the intracellular accumulation of **1a** and **4a** was significantly decreased compared to the free complexes. This observation already indicated that, despite the use of the same polyphosphazene nanocarrier, the individual polymer conjugates behaved markedly different in the performed biological assessments.

**Organ distribution.** In order to evaluate tolerability and organ distribution of the polymer-coupled complexes *in vivo*, studies in non-tumor bearing C57/B6JRj mice were carried out. In these experiments, the animals received a single dose of the drug conjugates **1a**, **2a** or **3a** *via* intravenous administration, while the biological investigation of **4a** was discontinued due to its insufficient metal-content as mentioned above. These experiments revealed that polymer-conjugate concentrations above  $50 \text{ mg kg}^{-1}$  were associated with severe (transient) fatigue. Consequently, for all subsequently performed *in vivo* experiments, concentrations of  $50 \text{ mg kg}^{-1}$  for **1a** and **3a**, and (due to the high drug loading)  $25 \text{ mg kg}^{-1}$  for **2a** were administered. The mice used for the tolerability tests were then sacrificed after 24 h and samples of blood, kidney, liver, lung, and, where possible, urine were collected. After microwave-assisted digestion of the tissue samples (25–50 mg) in half-concentrated nitric acid, the samples were diluted and the ruthenium or rhodium content was measured with ICP-MS. Conjugate **2a**

was administered in three different concentrations ( $100 \text{ mg kg}^{-1}$ ,  $50 \text{ mg kg}^{-1}$  and  $25 \text{ mg kg}^{-1}$  containing  $7.5 \text{ mg kg}^{-1}$ ,  $3.75 \text{ mg kg}^{-1}$  and  $1.9 \text{ mg kg}^{-1}$  ruthenium, respectively), while the conjugate **3a** was tested in two different concentrations ( $100 \text{ mg kg}^{-1}$  and  $50 \text{ mg kg}^{-1}$  containing  $3.25 \text{ mg kg}^{-1}$  and  $1.6 \text{ mg kg}^{-1}$  rhodium, respectively). In case of conjugate **1a**, a concentration of  $100 \text{ mg kg}^{-1}$  containing  $1.2 \text{ mg kg}^{-1}$  of ruthenium was used. An overview of all tested schemes is given in the ESI (Table S2†). Each concentration and conjugate was tested in parallel in two mice to assess the reproducibility of the measured metal concentration in all analyzed tissues. Overall, the highest metal contents were found in the liver and kidneys, while only low concentrations were observed in the remaining samples (Fig. 4 and Table S3†). In general, the determined metal concentrations met the expected distribution profile well, since the administered conjugates prefer-



**Fig. 4** Organ distribution of **1a–3a** 24 h after treatment. Female C57/B6JRj mice were intravenously injected with  $100 \text{ mg kg}^{-1}$  of **1a** (containing  $1.2 \text{ mg kg}^{-1}$  Ru),  $25$ ,  $50$  and  $100 \text{ mg kg}^{-1}$  **2a** (containing  $1.9$ ,  $3.8$  and  $7.5 \text{ mg kg}^{-1}$  Ru, respectively) and  $50$  and  $100 \text{ mg kg}^{-1}$  **3a** (containing  $1.6$  and  $3.2 \text{ mg kg}^{-1}$  Rh, respectively). After 24 h, mice were anesthetized and blood as well as urine was collected by heart and bladder punctation, respectively, and together with liver, lung and kidney samples were analyzed with ICP-MS to determine the metal content. Abbreviations: CBC, cellular blood compartment.

**Table 4** Comparison of intracellular accumulation of ruthenium and rhodium after treatment with compounds **1–4** and **1–4a**

pg metal/ $10^4$ cells	SW480	CT-26
<b>1</b>	$215 \pm 89$	$90 \pm 34$
<b>1a</b>	$72 \pm 12$	$7 \pm 1$
<b>2</b>	<LOD <sup>a</sup>	<LOD
<b>2a</b>	$24 \pm 6$	$23 \pm 11$
<b>3</b>	$62 \pm 13$	$55 \pm 3$
<b>3a</b>	$932 \pm 14$	$635 \pm 13$
<b>4</b>	$302 \pm 24$	$187 \pm 10$
<b>4a</b>	<LOD	<LOD

<sup>a</sup> LOD: limit of detection.



entally accumulate in organs responsible for clearance and excretion.

Conjugates **2a** and **3a** containing thiomaltolato-coordinated Ru<sup>II</sup> and Rh<sup>III</sup> metal centers, respectively, exhibited very similar distribution profiles despite their different metal centers. Both accumulated preferentially in the liver with metal concentrations more than five times higher than in kidney samples. Contrary to the distribution profile of conjugate **1a** exhibited ruthenium levels twice as high in kidney tissue compared to liver samples. The obtained data suggests that the metal content in all examined organs scales linearly with the applied dose and is almost identical after normalization of the metal content in reference to the dosage (Fig. 4). Furthermore, it can be seen that organ distribution of the tested conjugates is mainly affected by the coordinated ligand systems, whereas the different metal centers appear to have no discernable effect.


Subsequently, a second drug distribution experiment was conducted on CT-26 tumor-bearing animals 3 h after intravenous drug treatment (at concentrations which were subsequently used for the anticancer activity experiments in the same tumor model). Again, each concentration and conjugate was tested in parallel in two mice. Comparable to the experiments performed 24 h after therapy, **1a**-treated animals again showed highest drug levels in the kidney, while after application of **2a** and **3a** the highest concentrations were found in the liver tissue (Fig. 5). The high drug levels in the urine (especially in case of **1a** and **3a**) compared to the animals investigated after 24 h, indicate a surprisingly high drug excretion during the first hours after treatment. As this effect

cannot be explained by simple chemical reasons, it is assumed to be based on biological transformation or metabolism of the conjugates, which need to be further investigated in depth in subsequent studies. Interestingly, in case of compound **2a** the ruthenium levels in the liver (in contrast to all other tissues) were approximately twice as high in the animals investigated after 24 h as of those examined after 3 h. This fact could indicate a time-dependent (maybe metabolism-associated) accumulation of **2a** in this tissue. The effect was weaker for **1a** and **3a**, where the hepatic levels after 3 h and 24 h were very similar. With regard to the drug accumulation in the tumor, the metal content of **2a** and **3a** was higher than of conjugate **1a**, which is in line with the higher drug loading of these two polymers.

**Anticancer activity *in vivo*.** With the intriguing organ distribution profile at hand, the antineoplastic effect of conjugates **1a**, **2a**, and **3a** was next assessed by treatment of tumor-bearing Balb/c mice using the syngeneic murine tumor model CT-26 comparable to the experiments on complexes 1–3 described above. The animals were treated with the respective drugs intravenously on days 3, 5, 7, 10, 12 and 14.

The applied doses were 50 mg kg<sup>-1</sup>, 25 mg kg<sup>-1</sup> and 50 mg kg<sup>-1</sup> (containing 2.7 mg kg<sup>-1</sup>, 7.7 mg kg<sup>-1</sup> and 6.5 mg kg<sup>-1</sup> of the particular active metal complex, respectively) for conjugates **1a**, **2a**, and **3a**, respectively. During the first week of treatment, tumor growth curves for single mice revealed that administration of the macromolecular prodrugs induced drastic tumor shrinkage in some animals (Fig. 6 and Fig. S9†). Within the tested series, this effect was most pronounced for the naphthoquinone-based Ru<sup>II</sup> conjugate **1a**. In contrast, no comparable tumor shrinkage was induced in the control group treated with 0.9% sodium chloride solution. However, this beneficial effect of our conjugates was only of a transient nature and diminished over the course of the treatment resulting in rapid tumor regrowth in most of the animals. Consequently, only in the case of conjugate **3a**, a trend towards improved overall survival was found (Fig. 6h). In addition, one of the animals treated with conjugate **1a**, experienced a long lasting tumor stabilization and thus an >100% increase in life span (Fig. 6d). With regard to the unloaded polymer, we observed (compared to the 0.9% NaCl-treated group) an increase of tumor ulceration, which necessitated an earlier sacrifice of the animals. Notably, the final dissection of the animals revealed no indications of severe organ damage comparable to the treatment with the free complexes 1–3 (Fig. S10 and S11†).


In order to get insights into the impact of repeated polymer application on the tissue distribution, samples from two mice that had to be sacrificed on day 17 (three days after the last treatment) were analyzed by ICP-MS (Fig. 7). One of these animals had been treated with compound **1a**, the other with compound **2a**. Overall, the metal content in the analyzed organs of these mice largely resembled the distribution profiles determined 3 h and 24 h after single dose administration. Interestingly, in case of **2a**, the ruthenium levels of serum and urine were 5- and 25-fold higher than in the animals investi-




**Fig. 5** Tissue distribution of **1a**–**3a** 3 h after treatment. Murine CT-26 cells ( $5 \times 10^5$ ) were injected subcutaneously into the right flank of female Balb/c mice ( $n = 2$  per group). Animals were treated once intravenously with the indicated concentrations of compounds **1a**, **2a** and **3a** on day 10 after tumor inoculation, when the tumors reached a size of  $\sim 250$  mm<sup>3</sup>. After 3 h, mice were anesthetized and blood as well as urine was collected by heart and bladder punctation, respectively, and together with liver, lung, kidney and tumor samples were analyzed with ICP-MS to determine the metal content. Abbreviations: CBC cellular blood compartment.







**Fig. 6** Anticancer activity of 1a–3a. Murine CT-26 cells ( $5 \times 10^5$ ) were injected subcutaneously into the right flank of female Balb/c mice ( $n = 4$  per group). Animals were treated intravenously with 1a, 2a and 3a. The applied doses were  $50 \text{ mg kg}^{-1}$  for 1a and 3a, and  $25 \text{ mg kg}^{-1}$  for 2a on day 3, 5, 7, 10, 12, and 14. Tumor growth curves of single CT-26-bearing animals under treatment with (a) 0.9% NaCl, (b) unloaded polymer, (c) 1a, (e) 2a and (g) 3a are shown. Figures (d), (f) and (h) display the overall survival of CT-26-bearing animals upon the indicated drug treatment.



**Fig. 7** Tissue distribution of conjugates in two animals after 2 weeks of drug treatment. Two animals of the experiment depicted in Fig. 6 were sacrificed on day 17 (3 days after the last application) due to tumor ulceration. Mice (one treated with 1a and one with 2a) were anesthetized and blood as well as urine was collected by heart and bladder punctuation, respectively, together with tissue samples for ICP-MS analyses.

gated 24 h after single dose application. Unfortunately, we did not succeed in collecting blood and urine samples of the animal treated with 1a. The values found in blood and urine samples of 2a indicate a distinctly prolonged plasma half-life time along with slow drug release from the macromolecule. This assumption is also supported by the observation that, although the sample collection happened 3 days after the last drug application, the ruthenium levels in kidney and liver of the repeatedly treated animals still were significantly above the ones observed 3 h after a single dose application of the two different drugs. The effect was especially pronounced for 2a, where the liver levels were about 6-fold higher than the ones detected 24 h after a single application, which supports the hypothesis that this polymer slowly accumulates over time in the hepatic tissue with only limited elimination. Since such a strong drug accumulation in the liver could lead to drug-induced tissue damage, a histological evaluation of the collected samples was performed. For this purpose, the organs of all animals that had received therapy over a period of two weeks were embedded in paraffin, stained with hematoxylin/eosin and were microscopically investigated. Representative pictures for 0.9% NaCl, unconjugated polymer, as well as for conjugates 1a, 2a and 3a are shown in the ESI (Fig. S11†).

Overall, no major organ injury was found, thus confirming the protective nature of our approach. Solely Bowman's space in kidney tissue showed some reduction upon treatment with 2a and 3a. Taken together, our drug distribution data indicate that despite the use of the same polymer for all three organometallic complexes, the organ distribution pattern as well as kinetics strongly differed. Moreover, the drug accumulation levels in the malignant tissue were not predictive for the *in vivo* anticancer activity, as 1a (with the lowest tumor accumulation) was the only drug resulting in distinct life prolongation of an animal, while 2a (with the highest tumor levels) had no visible impact on overall survival of the animals.

## Conclusions

Within this work organometallic complexes have been attached to polyphosphazene macromolecules to obtain metallodrug conjugates. The extent of drug loading of the polymers was determined by measurement of the metal content *via* ICP-MS analysis after microwave-assisted digestion. Highest metal levels were detected for conjugates 2a and 3a, both bearing thiomaltolate as chelating ligand. The obtained macromolecular prodrugs were found to be highly stable in neutral aqueous solution as confirmed by <sup>31</sup>P NMR spectroscopy and UV-Vis kinetic studies. The free drug was observed to be released under acidic conditions potentially enabling selective intracellular lysosomal release. The anti-proliferative potency of the free complexes was determined in different human cancer cell lines and compared to the respective polymer adduct. Thereby, we found that conjugation of the free organometallics to polyphosphazenes sig-



nificantly diminished the activity *in vitro* compared to the parent small molecule complexes. The potential of the developed polymer adducts as anticancer agents was elucidated *in vivo* and compared to the respective complexes. In contrast to the unconjugated drugs no morphological changes of the animals' organs were observed, confirming the stabilization of the highly active organometallics. Furthermore, pronounced tumor shrinkage after administration of the first dose of loaded polymer was observed for all tested conjugates and especially in the case of **1a**, the beneficial effect was evident as one mouse experienced increased survival time by more than 100%. However, this effect cannot be explained by increased drug accumulation, because **1a** showed both lowest polymer drug loading and cellular accumulation in CT-26 *in vitro* and *in vivo*. In addition, tissue distribution analysis revealed a totally different accumulation profile of **1a** compared to **2a** or **3a** which contrasts their respective anticancer activity. Conjugates **2a** and **3a** preferably accumulated in the liver, while **1a** caused highest metal levels in the kidneys. To preclude that the conjugates have a detrimental effect on organs with the highest accumulation level, liver and kidney tissues were evaluated histologically and microscopic images revealed no severe drug induced tissue damage. Overall **2a** and **3a** showed similar results in all biological studies and therefore an impact of the metal center (Ru and Rh) on the anticancer potential *in vivo* can be excluded. It appears more likely that the coordinated bioactive ligand scaffold is the main activity determining factor in this class of organometallics, since investigated conjugates do not show differences in size or drug release behavior. Overall, the conjugation of metallodrugs to poly(organo)phosphazenes is a promising approach for drug delivery. Stabilization of the reactive organometallics by this macromolecular drug formulation tremendously reduced the observed local adverse effects such as the deformation of organs. Based on the obtained results presented herein, the naphthoquinone-containing complex **1** is a promising candidate for further research regarding lead optimization and mode of action studies. Improvement of the poly(organo)phosphazenes concerning drug loading efficacy, and in particular the drug release kinetics, as well as an optimization of the hydrodynamic volume with the aim of extending blood retention times and exploiting the EPR effect might be promising approaches to further enhance the very positive *in vivo* effects of our conjugates.

## Acknowledgements

The authors acknowledge financial support from the Austrian Science Fund (FWF) (Grant No. P24659-N28) and the Fellingner Krebsforschungsverein. We are grateful to Sushilla van Schoonhoven for the skillful handling of cell cultures, to Anita Brandstetter and the team of the Histology Core Facility of the Institute of Cancer Research for competent technical assistance and Gerhard Zeitler for devoted animal care.

## Notes and references

- 1 K. Morrissey, T. Yuraszek, C.-C. Li, Y. Zhang and S. Kasichayanula, *Clin. Transl. Sci.*, 2016, **9**, 89–104.
- 2 J. Arrowsmith and P. Miller, *Nat. Rev. Drug Discovery*, 2013, **12**, 569–569.
- 3 D. Cook, D. Brown, R. Alexander, R. March, P. Morgan, G. Satterthwaite and M. N. Pangalos, *Nat. Rev. Drug Discovery*, 2014, **13**, 419–431.
- 4 H. Maeda, *Adv. Drug Delivery Rev.*, 2015, **91**, 3–6.
- 5 H. Maeda, J. Wu, T. Sawa, Y. Matsumura and K. Hori, *J. Controlled Release*, 2000, **65**, 271–284.
- 6 Y. Matsumura and H. Maeda, *Cancer Res.*, 1986, **46**, 6387–6392.
- 7 E. Miele, G. P. Spinelli, E. Miele, F. Tomao and S. Tomao, *Int. J. Nanomed.*, 2009, **4**, 99–105.
- 8 O. Dömötör, C. G. Hartinger, A. K. Bytzeck, T. Kiss, B. K. Keppler and E. A. Enyedy, *JBIC, J. Biol. Inorg. Chem.*, 2013, **18**, 9–17.
- 9 R. Haag and F. Kratz, *Angew. Chem., Int. Ed.*, 2006, **45**, 1198–1215.
- 10 E. Markovskiy, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin and R. Satchi-Fainaro, *J. Controlled Release*, 2012, **161**, 446–460.
- 11 H. R. Allcock, *Soft Matter*, 2012, **8**, 7521–7532.
- 12 S. Rothemund and I. Teasdale, *Chem. Soc. Rev.*, 2016, **45**, 5200–5215.
- 13 R. Song, Y. Joo Jun, J. Ik Kim, C. Jin and Y. S. Sohn, *J. Controlled Release*, 2005, **105**, 142–150.
- 14 J. Y. Yu, Y. J. Jun, S. H. Jang, H. J. Lee and Y. S. Sohn, *J. Inorg. Biochem.*, 2007, **101**, 1931–1936.
- 15 S.-C. Song, S. B. Lee, B. H. Lee, H.-W. Ha, K.-T. Lee and Y. S. Sohn, *J. Controlled Release*, 2003, **90**, 303–311.
- 16 H. Henke, K. Kryeziu, J. Banfić, S. Theiner, W. Körner, O. Brüggemann, W. Berger, B. K. Keppler, P. Heffeter and I. Teasdale, *Macromol. Biosci.*, 2016, **16**, 1239–1249.
- 17 B. M. Blunden and M. H. Stenzel, *J. Chem. Technol. Biotechnol.*, 2015, **90**, 1177–1195.
- 18 B. S. Murray, M. V. Babak, C. G. Hartinger and P. J. Dyson, *Coord. Chem. Rev.*, 2016, **306**(Part 1), 86–114.
- 19 R. Fernández, M. Melchart, A. Habtemariam, S. Parsons and P. J. Sadler, *Chem. – Eur. J.*, 2004, **10**, 5173–5179.
- 20 F. Wang, A. Habtemariam, E. P. L. van der Geer, R. Fernández, M. Melchart, R. J. Deeth, R. Aird, S. Guichard, F. P. A. Fabbiani, P. Lozano-Casal, I. D. H. Oswald, D. I. Jodrell, S. Parsons and P. J. Sadler, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 18269–18274.
- 21 C. M. Hackl, M. S. Legina, V. Pichler, M. Schmidlehner, A. Roller, O. Dömötör, E. A. Enyedy, M. A. Jakupec, W. Kandioller and B. K. Keppler, *Chem. – Eur. J.*, 2016, **22**, 17269–17281.
- 22 I. F. Tannock and D. Rotin, *Cancer Res.*, 1989, **49**, 4373–4384.
- 23 W. Kandioller, C. G. Hartinger, A. A. Nazarov, M. L. Kuznetsov, R. O. John, C. Bartel, M. A. Jakupec, V. B. Arion and B. K. Keppler, *Organometallics*, 2009, **28**, 4249–4251.
- 24 A. Kurzwehnart, W. Kandioller, S. Bächler, C. Bartel, S. Martic, M. Buczkowska, G. Mühlgassner, M. A. Jakupec, H.-B. Kraatz,



- P. J. Bednarski, V. B. Arion, D. Marko, B. K. Keppler and C. G. Hartinger, *J. Med. Chem.*, 2012, **55**, 10512–10522.
- 25 C. Korch, M. A. Spillman, T. A. Jackson, B. M. Jacobsen, S. K. Murphy, B. A. Lessey, V. C. Jordan and A. P. Bradford, *Gynecol. Oncol.*, 2012, **127**, 241–248.
- 26 A. E. Egger, C. Rappel, M. A. Jakupec, C. G. Hartinger, P. Heffeter and B. K. Keppler, *J. Anal. At. Spectrom.*, 2009, **24**, 51–61.
- 27 R. Zhu, L. Xing, X. Wang, C. Cheng, B. Liu and Y. Hu, *Synlett*, 2007, 2267–2271.
- 28 D. Brayton, F. E. Jacobsen, S. M. Cohen and P. J. Farmer, *Chem. Commun.*, 2006, 206–208.
- 29 M. Bennett, A. J. Burke and W. Ivo O'Sullivan, *Tetrahedron*, 1996, **52**, 7163–7178.
- 30 P.-S. Kuhn, V. Pichler, A. Roller, M. Hejl, M. A. Jakupec, W. Kandioller and B. K. Keppler, *Dalton Trans.*, 2015, **44**, 659–668.
- 31 H. Henke, O. Brüggemann and I. Teasdale, *Macromol. Rapid Commun.*, 2017, **38**, 1600644.
- 32 M. E. Fox, F. C. Szoka and J. M. J. Fréchet, *Acc. Chem. Res.*, 2009, **42**, 1141–1151.
- 33 H. Henke, S. Wilfert, A. Iturmendi, O. Brüggemann and I. Teasdale, *J. Polym. Sci., Part A: Polym. Chem.*, 2013, **51**, 4467–4473.
- 34 H. Henke, S. Posch, O. Brüggemann and I. Teasdale, *Macromol. Rapid Commun.*, 2016, **37**, 769–774.
- 35 S. Wilfert, A. Iturmendi, W. Schoefberger, K. Kryeziu, P. Heffeter, W. Berger, O. Brüggemann and I. Teasdale, *J. Polym. Sci., Part A: Polym. Chem.*, 2014, **52**, 287–294.
- 36 R. Duncan, *Nat. Rev. Drug Discovery*, 2003, **2**, 347–360.
- 37 R. Duncan, *Nat. Rev. Cancer*, 2006, **6**, 688–701.
- 38 R. Duncan and S. C. W. Richardson, *Mol. Pharm.*, 2012, **9**, 2380–2402.

